Category REGENERATIVE MEDICINE

PIER MARIA FORNASARI
2022-08-18

FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

The U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing red blood cell transfusions,” said Peter

Read More

One comment InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-08-17

Stem cell-based therapy for human diseases: a complete review

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2022-08-12

Two patients treated with Novartis Zolgensma gene therapy died due to acute liver injury.

Two children who received a Novartis gene therapy for their neuromuscular disease died following treatment, spotlighting its risks and renewing questions about the safety of genetic medicines like it. The patients developed acute liver failure between five and six weeks after infusion with the gene therapy, called Zolgensma and approved to treat spinal muscular atrophy,

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT GENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-08-09

Higher doses of CAR T cell therapy associate with improved outcomes in young patients with B-ALL : a report from the pediatric real-world CAR consortium

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.   Since its approval as the first

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-08-06

St. Jude Researchers improved CAR T-cell therapy for T-cell acute lymphoblastic leukemia

Scientists at St. Jude Children’s Research Hospital developed a simple method to select for more effective cancer-destroying CAR T cells for patients with relapsed T-ALL. Scientists at St. Jude Children’s Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed promise in the lab against relapsed T-cell

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-08-03

Gene Therapy Approach Shows Promise in Treating ALS

In rodent models, introduced neuroprotective protein slowed disease progression and increased life span Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons in the brain and spinal cord responsible for voluntary movements and muscle control. In a new study, published July 11, 2022 in the journal Theranostics, researchers at

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-06-12

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

CNS relapse is still a common cause of treatment failure in R/R B-ALL, although chemotherapy, cranial irradiation, and allo-HSCT are all modalities that can be incorporated into the management of CNSL. In the present study, published on Blood by a team of Xuzhou Medical University, was reported the efficacy, toxicity, and clinical feasibility of CD19-specific

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-06-12

First successful treatment of severe pulmonary hypertension using umbilical cord stem cells

Hannover Medical School doctors successfully treat three-year-old girl / Publication in “Nature Cardiovascular Research“ Clinical researchers at Hannover Medical School (MHH) have succeeded for the first time worldwide in stopping the usually fatal course of the disease in severe pulmonary hypertension thanks to a novel therapeutic approach. A three-year-old girl suffering from so-called pulmonary arterial

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT CELL THERAPY